Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial.
Identifieur interne : 002B40 ( PubMed/Corpus ); précédent : 002B39; suivant : 002B41Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial.
Auteurs : Jacques Montplaisir ; Jeff Karrasch ; Jean Haan ; Dieter VolcSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2006.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Dopamine Agonists (adverse effects), Dopamine Agonists (therapeutic use), Double-Blind Method, Drug Therapy, Combination, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Indoles (adverse effects), Indoles (therapeutic use), Long-Term Care, Male, Middle Aged, Restless Legs Syndrome (drug therapy), Single-Blind Method, Treatment Outcome.
- MESH :
- chemical , adverse effects : Dopamine Agonists, Indoles.
- chemical , therapeutic use : Dopamine Agonists, Indoles.
- drug therapy : Restless Legs Syndrome.
- Adolescent, Adult, Aged, Double-Blind Method, Drug Therapy, Combination, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Long-Term Care, Male, Middle Aged, Single-Blind Method, Treatment Outcome.
Abstract
The objective of this study was to investigate the long-term efficacy of ropinirole in patients with restless legs syndrome (RLS) and to assess the potential for relapse after the discontinuation of active treatment. Patients with primary RLS (n = 202) received single-blind ropinirole for 24 weeks. Patients meeting treatment continuation criteria were randomized to double-blind treatment with ropinirole or placebo for a further 12 weeks. The primary efficacy variable was the proportion of patients relapsing during double-blind treatment. Additional efficacy measures included time to relapse, withdrawals due to lack of efficacy, improvement on the Clinical Global Impression-Improvement (CGI-I) scale, change in International Restless Legs Scale (IRLS) score during double-blind treatment, and changes in sleep and quality of life (QoL) parameters. Significantly fewer patients relapsed on ropinirole than on placebo (32.6% vs. 57.8%; P = 0.0156). Time to relapse was longer with ropinirole and more patients withdrew due to lack of efficacy with placebo. Patients showed improvements in IRLS and CGI-I scores, sleep and QoL parameters with single-blind ropinirole, which were better maintained when ropinirole was continued during the double-blind phase, but reduced with placebo. Ropinirole was well tolerated; adverse events were typical for dopamine agonists. Ropinirole was highly effective and well tolerated in the long-term management of RLS, with pharmacological effect over 36 weeks.
DOI: 10.1002/mds.21050
PubMed: 16874755
Links to Exploration step
pubmed:16874755Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial.</title>
<author><name sortKey="Montplaisir, Jacques" sort="Montplaisir, Jacques" uniqKey="Montplaisir J" first="Jacques" last="Montplaisir">Jacques Montplaisir</name>
<affiliation><nlm:affiliation>Sleep Disorders Clinic, Hôpital du Sacré-Coeur de Montréal, Montréal, Quebec, Canada. j-montplaisir@crhsc.umontreal.ca</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Karrasch, Jeff" sort="Karrasch, Jeff" uniqKey="Karrasch J" first="Jeff" last="Karrasch">Jeff Karrasch</name>
</author>
<author><name sortKey="Haan, Jean" sort="Haan, Jean" uniqKey="Haan J" first="Jean" last="Haan">Jean Haan</name>
</author>
<author><name sortKey="Volc, Dieter" sort="Volc, Dieter" uniqKey="Volc D" first="Dieter" last="Volc">Dieter Volc</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="doi">10.1002/mds.21050</idno>
<idno type="RBID">pubmed:16874755</idno>
<idno type="pmid">16874755</idno>
<idno type="wicri:Area/PubMed/Corpus">002B40</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial.</title>
<author><name sortKey="Montplaisir, Jacques" sort="Montplaisir, Jacques" uniqKey="Montplaisir J" first="Jacques" last="Montplaisir">Jacques Montplaisir</name>
<affiliation><nlm:affiliation>Sleep Disorders Clinic, Hôpital du Sacré-Coeur de Montréal, Montréal, Quebec, Canada. j-montplaisir@crhsc.umontreal.ca</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Karrasch, Jeff" sort="Karrasch, Jeff" uniqKey="Karrasch J" first="Jeff" last="Karrasch">Jeff Karrasch</name>
</author>
<author><name sortKey="Haan, Jean" sort="Haan, Jean" uniqKey="Haan J" first="Jean" last="Haan">Jean Haan</name>
</author>
<author><name sortKey="Volc, Dieter" sort="Volc, Dieter" uniqKey="Volc D" first="Dieter" last="Volc">Dieter Volc</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Dopamine Agonists (adverse effects)</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Drug-Related Side Effects and Adverse Reactions</term>
<term>Female</term>
<term>Humans</term>
<term>Indoles (adverse effects)</term>
<term>Indoles (therapeutic use)</term>
<term>Long-Term Care</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Restless Legs Syndrome (drug therapy)</term>
<term>Single-Blind Method</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dopamine Agonists</term>
<term>Indoles</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agonists</term>
<term>Indoles</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Restless Legs Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Double-Blind Method</term>
<term>Drug Therapy, Combination</term>
<term>Drug-Related Side Effects and Adverse Reactions</term>
<term>Female</term>
<term>Humans</term>
<term>Long-Term Care</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Single-Blind Method</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The objective of this study was to investigate the long-term efficacy of ropinirole in patients with restless legs syndrome (RLS) and to assess the potential for relapse after the discontinuation of active treatment. Patients with primary RLS (n = 202) received single-blind ropinirole for 24 weeks. Patients meeting treatment continuation criteria were randomized to double-blind treatment with ropinirole or placebo for a further 12 weeks. The primary efficacy variable was the proportion of patients relapsing during double-blind treatment. Additional efficacy measures included time to relapse, withdrawals due to lack of efficacy, improvement on the Clinical Global Impression-Improvement (CGI-I) scale, change in International Restless Legs Scale (IRLS) score during double-blind treatment, and changes in sleep and quality of life (QoL) parameters. Significantly fewer patients relapsed on ropinirole than on placebo (32.6% vs. 57.8%; P = 0.0156). Time to relapse was longer with ropinirole and more patients withdrew due to lack of efficacy with placebo. Patients showed improvements in IRLS and CGI-I scores, sleep and QoL parameters with single-blind ropinirole, which were better maintained when ropinirole was continued during the double-blind phase, but reduced with placebo. Ropinirole was well tolerated; adverse events were typical for dopamine agonists. Ropinirole was highly effective and well tolerated in the long-term management of RLS, with pharmacological effect over 36 weeks.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16874755</PMID>
<DateCreated><Year>2006</Year>
<Month>10</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted><Year>2007</Year>
<Month>02</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>21</Volume>
<Issue>10</Issue>
<PubDate><Year>2006</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial.</ArticleTitle>
<Pagination><MedlinePgn>1627-35</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The objective of this study was to investigate the long-term efficacy of ropinirole in patients with restless legs syndrome (RLS) and to assess the potential for relapse after the discontinuation of active treatment. Patients with primary RLS (n = 202) received single-blind ropinirole for 24 weeks. Patients meeting treatment continuation criteria were randomized to double-blind treatment with ropinirole or placebo for a further 12 weeks. The primary efficacy variable was the proportion of patients relapsing during double-blind treatment. Additional efficacy measures included time to relapse, withdrawals due to lack of efficacy, improvement on the Clinical Global Impression-Improvement (CGI-I) scale, change in International Restless Legs Scale (IRLS) score during double-blind treatment, and changes in sleep and quality of life (QoL) parameters. Significantly fewer patients relapsed on ropinirole than on placebo (32.6% vs. 57.8%; P = 0.0156). Time to relapse was longer with ropinirole and more patients withdrew due to lack of efficacy with placebo. Patients showed improvements in IRLS and CGI-I scores, sleep and QoL parameters with single-blind ropinirole, which were better maintained when ropinirole was continued during the double-blind phase, but reduced with placebo. Ropinirole was well tolerated; adverse events were typical for dopamine agonists. Ropinirole was highly effective and well tolerated in the long-term management of RLS, with pharmacological effect over 36 weeks.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Montplaisir</LastName>
<ForeName>Jacques</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Sleep Disorders Clinic, Hôpital du Sacré-Coeur de Montréal, Montréal, Quebec, Canada. j-montplaisir@crhsc.umontreal.ca</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Karrasch</LastName>
<ForeName>Jeff</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Haan</LastName>
<ForeName>Jean</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Volc</LastName>
<ForeName>Dieter</ForeName>
<Initials>D</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016448">Multicenter Study</PublicationType>
<PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>030PYR8953</RegistryNumber>
<NameOfSubstance UI="C046649">ropinirole</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D018491">Dopamine Agonists</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D064420">Drug-Related Side Effects and Adverse Reactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D007211">Indoles</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008134">Long-Term Care</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D012148">Restless Legs Syndrome</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016037">Single-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year>
<Month>7</Month>
<Day>29</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2007</Year>
<Month>2</Month>
<Day>3</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2006</Year>
<Month>7</Month>
<Day>29</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="doi">10.1002/mds.21050</ArticleId>
<ArticleId IdType="pubmed">16874755</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B40 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002B40 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:16874755 |texte= Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:16874755" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
This area was generated with Dilib version V0.6.23. |